Elevated expression of CUEDC2 protein confers endocrine resistance in breast cancer

Xin Pan,Tao Zhou,Yan-Hong Tai,Chenguang Wang,Jie Zhao,Yuan Cao,Yuan Chen,Pei-Jing Zhang,Ming Yu,Cheng Zhen,Rui Mu,Zhao-Fang Bai,Hui-Yan Li,Ai-Ling Li,Bing Liang,Zhao Jian,Wei-Na Zhang,Jiang-Hong Man,Yan-Fei Gao,Wei-Li Gong,Li-Xin Wei,Xue-Min Zhang

DOI: https://doi.org/10.1038/nm.2369

IF: 82.9

2011-01-01

Nature Medicine

Abstract:Downregulation of estrogen receptor-α (ER-α) in breast tumors can mediate resistance to ER-α–targeted therapies such as tamoxifen. This report sheds light on a therapy resistance–conferring adaptation by identifying a new regulator of ER-α stability. CUE domain–containing protein-2 (CUEDC2) can bind to and promote degradation of ER-α, thereby driving tamoxifen resistance. Elevated CUEDC2 elevation in human breast cancers correlates with attenuated prognosis after tamoxifen treatment, thus suggesting its potential as a clinical predictor.